Coherus Oncology (CHRS) Cash from Financing Activities (2014 - 2026)

Coherus Oncology has reported Cash from Financing Activities for 13 years, with the latest figure at $53.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 20399.24% year-over-year to $53.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$219.9 million (down 16.86% YoY) and the FY2025 annual result came in at -$273.7 million, down 46.39% from the prior year.
• Cash from Financing Activities climbed to $53.6 million in Q1 2026 per CHRS's latest filing, from $8.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $54.3 million in Q2 2023 and troughed at -$281.5 million in Q2 2025.
• A 5-year average of -$16.7 million and a median of $721000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities tumbled 445.93% in 2024, then jumped 20399.24% in 2026.
• Over 5 years, Cash from Financing Activities stood at $6.6 million in 2022, then sank by 94.45% to $366000.0 in 2023, then sank by 36.89% to $231000.0 in 2024, then surged by 3398.27% to $8.1 million in 2025, then surged by 563.16% to $53.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $53.6 million, $8.1 million, and $2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.